Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CLRB Stock Summary
Top 10 Correlated ETFs
CLRB
In the News

Here's Why Cellectar Biosciences Shares Are Rising
Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus an estimate of a.

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week
5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed John Friend MD, the former chief medical officer (CMO) at Cellectar Biosciences (NASDAQ:CLRB), Inc as its new CMO. Dr Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and collaborate with clinicians and scientists to advance the company's research programs.

Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer
Cellectar Biosciences Inc (NASDAQ: CLRB) has completed part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relapsed or refractory head and neck cancer. Related: Cellectar Receives $2M NIH Grant For Rare Lymphoma Study.

Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview at the following upcoming conference:

Cellectar Receives $2M NIH Grant For Rare Lymphoma Study
Cellectar Biosciences Inc (NASDAQ: CLRB) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the National Cancer Institute (NCI). The Company is currently conducting a pivotal study of iopofosine I-131 (CLR 131) in Waldenstrom's macroglobulinemia (WM) patients who have received at least two prior lines of therapy.

Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia
FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 Million from the National Cancer Institute (NCI).

Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131
Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131)

Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update
FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.
CLRB Financial details
CLRB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -44.7 | -18.36 | -7.62 | -4.35 | -4.05 | |
Operating cash flow per share | -38.63 | -15.24 | -7.03 | -4.07 | 0 | |
Free cash flow per share | -39.93 | -15.27 | -7.06 | -4.09 | -0.03 | |
Cash per share | 44.75 | 13.83 | 28.85 | 6.43 | 2.82 | |
Book value per share | 44.77 | 11.8 | 27.66 | 5.95 | 2.2 | |
Tangible book value per share | 44.77 | 11.8 | 27.66 | 5.95 | 2.2 | |
Share holders equity per share | 44.77 | 11.8 | 27.66 | 5.95 | 2.2 | |
Interest debt per share | 0.11 | 0.74 | 0.22 | 0.05 | 0.09 | |
Market cap | 4.59M | 17.27M | 41.21M | 36.86M | 12.07M | |
Enterprise value | -8.66M | 7.18M | -15.53M | 1.46M | -7.2M | |
P/E ratio | -0.35 | -1.23 | -2.73 | -1.53 | -0.42 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.4 | -1.48 | -2.96 | -1.63 | 0 | |
PFCF ratio | -0.39 | -1.47 | -2.94 | -1.62 | -53.39 | |
P/B Ratio | 0.35 | 1.91 | 0.75 | 1.12 | 0.78 | |
PTB ratio | 0.35 | 1.91 | 0.75 | 1.12 | 0.78 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0.66 | -0.52 | 1.04 | -0.06 | 0.25 | |
EV to operating cash flow | 0.76 | -0.61 | 1.11 | -0.06 | 0 | |
EV to free cash flow | 0.73 | -0.61 | 1.11 | -0.06 | 31.85 | |
Earnings yield | -2.88 | -0.82 | -0.37 | -0.65 | -2.37 | |
Free cash flow yield | -2.58 | -0.68 | -0.34 | -0.62 | -0.02 | |
Debt to equity | 0.14 | 0.35 | 0.07 | 0.13 | 0.39 | |
Debt to assets | 0.12 | 0.26 | 0.07 | 0.11 | 0.28 | |
Net debt to EBITDA | 1.01 | 0.72 | 3.8 | 1.48 | 0.68 | |
Current ratio | 8.6 | 4.11 | 16.26 | 9.16 | 3.71 | |
Interest coverage | -392.61 | -331.96 | -1.4K | -10.57K | 0 | |
Income quality | 0.86 | 0.83 | 0.92 | 0.94 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | 0 | 0 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -4.68 | -0.18 | -0.44 | -0.94 | -1.52 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 212.19 | 69.83 | 68.85 | 24.12 | 14.16 | |
ROIC | 0.97 | 1.38 | 0.27 | 0.68 | 1.58 | |
Return on tangible assets | -0.88 | -1.15 | -0.26 | -0.65 | -1.32 | |
Graham Net | 38.7 | 9.67 | 26.9 | 5.68 | 1.95 | |
Working capital | 12.33M | 8.62M | 54.38M | 32.58M | 15M | |
Tangible asset value | 13.26M | 9.06M | 54.79M | 33.05M | 15.51M | |
Net current asset value | 12.16M | 8.19M | 54.07M | 32.41M | 14.45M | |
Invested capital | 0 | 0.06 | 0.01 | 0.01 | 0.04 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 306K | 945K | 1.35M | 1.42M | 707.5K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1 | -1.56 | -0.28 | -0.73 | -1.84 | |
Capex per share | -1.3 | -0.03 | -0.03 | -0.03 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.99 | -1 | -1.22 | -1.28 | -1.02 | |
Operating cash flow per share | -0.75 | -0.82 | -0.94 | -1.15 | 0 | |
Free cash flow per share | -0.78 | -0.83 | -0.95 | -1.15 | 2.51 | |
Cash per share | 5.96 | 5.01 | 4.06 | 2.91 | 2.82 | |
Book value per share | 5.52 | 4.45 | 3.31 | 2.09 | 2.2 | |
Tangible book value per share | 5.52 | 4.45 | 3.31 | 2.09 | 2.2 | |
Share holders equity per share | 5.52 | 4.45 | 3.31 | 2.09 | 2.2 | |
Interest debt per share | 0.05 | 0.04 | 0.04 | 0.03 | 0.09 | |
Market cap | 39.75M | 42.03M | 24.67M | 20.53M | 12.07M | |
Enterprise value | 4.35M | 11.66M | 103.17K | 2.95M | -7.2M | |
P/E ratio | -1.68 | -1.71 | -0.83 | -0.66 | -0.42 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -8.81 | -8.34 | -4.29 | -2.93 | 0 | |
PFCF ratio | -8.57 | -8.29 | -4.23 | -2.92 | 0.68 | |
P/B Ratio | 1.2 | 1.54 | 1.22 | 1.61 | 0.78 | |
PTB ratio | 1.2 | 1.54 | 1.22 | 1.61 | 0.78 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -0.74 | -1.91 | -0.01 | -0.38 | 0.99 | |
EV to operating cash flow | -0.96 | -2.31 | -0.02 | -0.42 | 0 | |
EV to free cash flow | -0.94 | -2.3 | -0.02 | -0.42 | -0.41 | |
Earnings yield | -0.15 | -0.15 | -0.3 | -0.38 | -0.6 | |
Free cash flow yield | -0.12 | -0.12 | -0.24 | -0.34 | 1.47 | |
Debt to equity | 0.13 | 0.18 | 0.28 | 0.52 | 0.39 | |
Debt to assets | 0.11 | 0.15 | 0.22 | 0.34 | 0.28 | |
Net debt to EBITDA | 6.02 | 4.98 | 3.32 | 2.26 | 2.66 | |
Current ratio | 9.16 | 6.75 | 4.51 | 2.88 | 3.71 | |
Interest coverage | 4.46K | -14.28K | -15.46K | -1.88K | 0 | |
Income quality | 0.76 | 0.82 | 0.77 | 0.9 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | 0.01 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -3.3 | -0.69 | -2.09 | -0.21 | -3.09 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 11.08 | 10.03 | 9.51 | 7.75 | 7.11 | |
ROIC | 0.17 | 0.21 | 0.31 | 0.48 | 0.41 | |
Return on tangible assets | -0.16 | -0.19 | -0.29 | -0.4 | -0.33 | |
Graham Net | 5.27 | 4.23 | 3.13 | 1.84 | 1.95 | |
Working capital | 32.58M | 26.74M | 19.68M | 12.25M | 15M | |
Tangible asset value | 33.05M | 27.21M | 20.19M | 12.75M | 15.51M | |
Net current asset value | 32.41M | 26.61M | 19.59M | 12.19M | 14.45M | |
Invested capital | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 707.5K | 707.5K | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.18 | -0.23 | -0.37 | -0.61 | -0.47 | |
Capex per share | -0.02 | 0 | -0.01 | 0 | -0.02 |
CLRB Frequently Asked Questions
What is Cellectar Biosciences, Inc. stock symbol ?
Cellectar Biosciences, Inc. is a US stock , located in Florham park of Nj and trading under the symbol CLRB
What is Cellectar Biosciences, Inc. stock quote today ?
Cellectar Biosciences, Inc. stock price is $1.54 today.
Is Cellectar Biosciences, Inc. stock public?
Yes, Cellectar Biosciences, Inc. is a publicly traded company.